Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

34 of the most innovative pharmaceutical products

By Brian Buntz | July 21, 2021

innovative pharmaceutical products pharmaceuticals

Photo by Myriam Zilles on Unsplash

The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products.

Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to make its selections.

The organization will announce the final competition winners at a ceremony in New York City on Oct. 28, 2021. 

[Related: The most innovative pharmaceutical agents of 2020] 

In terms of pharmaceutical agents, the organization selected the following 34 nominees:

Company

Drug name

AbbVie Inc.

Rinvoq (upadacitinib)

Adlon Therapeutics L.P., a subsidiary of Purdue Pharma 

Adhansia XR (methylphenidate HCI)

Advanced Accelerator Applications USA, Inc., a Novartis company

Lutathera (lutetium Lu 177 dotatate)

Astellas Pharma Inc.

Xospata  (gilteritinib)

Bayer U.S., LLC

Nubeqa (darolutamide)

Bayer U.S., LLC

Vitrakvi  (larotrectinib)

Biohaven Pharmaceuticals

Nurtec ODT (rimegepant)

Blueprint Medicines

Ayvakit (avapritinib)

Blueprint Medicines

Gavreto (pralsetinib)

Deciphera Pharmaceuticals

Qinlock (ripretinib)

Eiger BioPharmaceuticals, Inc.

Zokinvy (lonafarnib)

Eli Lilly & Company

Olumiant (baricitinib)

Eli Lilly & Company

Reyvow (lasmiditan)

Epizyme Inc.

Tazverik (tazemetostat)

Esperion Therapeutics Inc.

Nexlizet (bempedoic acid and ezetimibe)

Esperion Therapeutics Inc.

Nexletol (bempedoic acid)

Genentech, a member of the Roche Group

Rozlytrek (entrectinib)

Gilead Sciences, Inc.

Veklury (remdesivir)

Incyte

Pemazyre (pemigatinib)

Karyopharm Therapeutics Inc.

Xpovio (selinexor)

Medicines Development for Global Health

Moxidectin

Merck & Co., Inc.

Recarbrio (imipenem, cilastatin and relebactam)

Myovant Sciences, Inc.

Orgovyx (relugolix)

Novartis Pharmaceuticals Corporation

Adakveo (crizanlizumab)

Novartis Pharmaceuticals Corporation

Entresto (sacubitril/valsartan)

Novartis Pharmaceuticals Corporation

Piqray (alpelisib)

Pfizer Inc.

Braftovi Mektovi (encorafenib/binimetinib)

Pfizer Inc.

Lorbrena (lorlatinib)

Population Council

Annovera (segesterone acetate and ethinyl estradiol)

Seagen

Tukysa (tucatinib)

Servier Pharmaceuticals

Asparlas (calaspargase pegol-mknl injection)

SIGA Technologies, Inc.

Tpoxx (tecovirimat)

Sobi, Inc.

Gamifant (emapalumab-lzsg)

Dr. Reddy’s Laboratories, Inc.

Elyxyb (celecoxib)


Filed Under: Cardiovascular, Dermatology, Drug Discovery, Infectious Disease, Neurological Disease, Oncology, Rheumatology
Tagged With: AbbVie, Adakveo, Adhansia XR, Adlon Therapeutics, Advanced Accelerator Applications, Asparlas, Astellas Pharma, AYVAKIT, Bayer, Biohaven Pharmaceuticals, Blueprint Medicines, Braftovi Mektovi, Deciphera Pharmaceuticals, Dr. Reddy's Laboratories, Eiger BioPharmaceuticals, Eli Lilly, ELYXYB, Entresto, Epizyme Inc., Esperion Therapeutics, Gamifant, GAVRETO, Genentech, Gilead Sciences, Incyte, Karyopharm Therapeutics, Lorbrena, Lutathera, Merck, Moxidectin, Myovant Sciences, NEXLETOL, NEXLIZET, Novartis, NUBEQA, Nurtec ODT, Olumiant, Orgovyx, Pemazyre, Pfizer, PIQRAY, Purdue Pharma, QINLOCK, RECARBRIO, remdesivir, REYVOW, Rinvoq, Roche, Rozlytrek, Seagen, Servier Pharmaceuticals, SIGA, Sobi, TAZVERIK, TPOXX, Tukysa, Veklury, VITRAKVI, XOSPATA, XPOVIO, ZOKINVY
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE